FDA delays ruling on AstraZeneca drug after negative adcomm vote - Fierce Biotech

FDA delays ruling on AstraZeneca drug after negative adcomm vote    Fierce Biotech US regulator delays decision on AstraZeneca cancer drug    Financial Times Camizestrant in combination with a CDK4/6 inhibitor recommended for approval in the EU by CHMP for 1st-line advanced ER-positive breast cancer    AstraZeneca AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave    Endpoints News AstraZeneca’s ‘game changer’ cancer pill stuck in limbo as FDA demands more data    The Independent

Original source: Google News GB